CClinicalTrials.gg
CompletedNCT06154616MilcaUpdated Feb 16, 2024

Efficacy of Different Types of Milk in Improving Sleep Quality in Subjects With Sleep Problems (Milca)

An interventional study of Control Product and Experimental Product: 250 in Poor Quality Sleep, sponsored by Universidad Católica San Antonio de Murcia. Completed at 1 site in Spain. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-16.

Sponsored by Universidad Católica San Antonio de Murcia · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Randomized, controlled, double-blind intervention study, with four parallel branches depending on the product consumed, to analyze the efficacy of different types of milks on the improvement of sleep quality.

Read the detailed description

The duration of the study will be 90 days (12 weeks). Each day they will have to consume the product under investigation. The subjects who meet the selection criteria will be randomly distributed in each of the study groups (A, B, C or D, depending on the group in which they have been randomized). Each day the subjects will have to fill in a diary on sleep quality and concomitant medication.

They will make a total of two visits to the research laboratory and the tests preestablished in the protocol will be performed. Subsequently, a statistical analysis will be performed with the variables measured in the study to obtain the results.

02

Conditions studied

  • Poor Quality Sleep

Keywords

  • Ashwagandha extract
  • tryptophan
03

In context

Dyssomnias

324 studies on the registry are indexed under Dyssomnias; 51 are open to participants now.

This study's enrollment of 52 is below the median of 60 across 251 interventional studies indexed under Dyssomnias.

Browse Dyssomnias studies →

Lead sponsor

Universidad Católica San Antonio de Murcia is the lead sponsor of 132 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy adults (> 18 years).
  • Low sleep quality by Pittsburgh Sleep Quality Questionnaire (PSQI).
  • Volunteers able to understand the clinical study and willing to comply with the study procedures and requirements.

Exclusion criteria

Exclusion Criteria:

  • Subjects with serious or terminal illnesses.
  • Subjects with known allergy or hypersensitivity to any of the components of the investigational product.
  • Participation in another study involving blood draws or dietary intervention.
  • Subjects with body mass index above 32 kg/m2.
  • Pregnant or lactating women.
  • Use of medications that alter cognitive functions or sleep, such as barbiturates, anticonvulsants, benzodiazepines, antidepressants, neuroleptics, alcohol and illicit drugs.
  • Organic dementias such as Alzheimer's, Huntington's disease, Parkinson's and senile dementia.
  • Inability to understand informed consent (IC).
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Placebo comparator
    Control

    Subjects will consume 250 ml of milk half an hour before bedtime.

    Dietary Supplement: Control Product

  • Experimental
    Ashw 250

    Subjects will consume 250 ml of milk half an hour before bedtime.

    Dietary Supplement: Experimental Product: 250

  • Experimental
    Ashw 250 + TRP

    Subjects will consume 250 ml of milk half an hour before bedtime.

    Dietary Supplement: Experimental Product: 250 + TRP

  • Experimental
    Ashw 600

    Subjects will consume 250 ml of milk half an hour before bedtime.

    Dietary Supplement: Experimental Product: 600

Interventions

  • Dietary supplementControl Product

    Lactose-free skimmed milk

  • Dietary supplementExperimental Product: 250

    Lactose-free skimmed milk enriched with 250 mg aswaghanda

  • Dietary supplementExperimental Product: 250 + TRP

    Lactose-free skimmed milk enriched with 250 mg aswaghanda and tryptophan

  • Dietary supplementExperimental Product: 600

    Lactose-free skimmed milk enriched with 600 mg aswaghanda

06

What researchers measure

Primary outcomes

  1. Variation in sleep quality from baseline at 12 weeks.

    Visual analog scale from 0 to 10. The higher the value, the more quality.

    Time frame: The evolution of sleep quality after consumption during 12 weeks will be measured.

Secondary outcomes

  1. Change in Sleep Quality from baseline at 12 weeks

    Visual analog scale from 0 to 10. The higher the value, the more quality.

    Time frame: Sleep quality will be measured with a daily scale, from baseline to 12 weeks.

  2. Sleep quality

    Measured by Pittsburgh test

    Time frame: It will be measured twice, once at baseline or at the end of the study after 12 weeks of use

  3. Insomnia severity

    Measured by Insomnia severity index - ISI test

    Time frame: It will be measured twice, once at baseline or at the end of the study after 12 weeks of use

  4. Sleepiness

    Measured by Epworth test

    Time frame: It will be measured twice, once at baseline or at the end of the study after 12 weeks of use

  5. Matutinity - Verpertinity

    Measured by Matutinity - Verpertinity questionnaire

    Time frame: It will be measured twice, once at baseline or at the end of the study after 12 weeks of use

  6. Anxiety questionnaire

    Test STAI, to measure the level of anxiety of the subjects

    Time frame: Day 1, at 12 weeks later

  7. Body composition

    It is a control variable. Measured by bioimpedance

    Time frame: The test will be measured at baseline and after 12 weeks of consumption.

  8. Adverse events

    It will be evaluated at each of the visits.

    Time frame: At 12 weeks after consumption

07

Study locations

1 site
  • Catholic University of Murcia
    Murcia, 30107, Spain
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06154616
Lead sponsor
Universidad Católica San Antonio de Murcia
Responsible party
Francisco Javier López Román (Principal Investigator, Universidad Católica San Antonio de Murcia) — Principal investigator
First posted
Dec 4, 2023
Start date
Sep 15, 2023
Primary completion
Dec 20, 2023
Completion
Jan 19, 2024
Last update
Feb 16, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion